Anchor Capital Advisors LLC Sells 20,844 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Anchor Capital Advisors LLC cut its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 21.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 76,698 shares of the medical research company’s stock after selling 20,844 shares during the period. Anchor Capital Advisors LLC’s holdings in Bio-Rad Laboratories were worth $24,765,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BIO. GAMMA Investing LLC purchased a new stake in Bio-Rad Laboratories in the fourth quarter worth approximately $42,000. ING Groep NV bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth approximately $44,000. Bfsg LLC purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $77,000. Signaturefd LLC grew its holdings in shares of Bio-Rad Laboratories by 15.8% during the 4th quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 48 shares during the last quarter. Finally, Banque Cantonale Vaudoise boosted its position in Bio-Rad Laboratories by 25.0% during the third quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock valued at $135,000 after buying an additional 75 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of recent research reports. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Royal Bank of Canada dropped their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. UBS Group lifted their target price on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $468.00.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares in the company, valued at $2,332,512. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 17.50% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Stock Performance

Shares of BIO traded up $1.17 during mid-day trading on Monday, hitting $277.11. 149,394 shares of the company’s stock traded hands, compared to its average volume of 202,293. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34. The business’s 50-day moving average price is $324.94 and its 200-day moving average price is $316.96. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $473.50.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business had revenue of $681.18 million for the quarter, compared to the consensus estimate of $685.00 million. During the same period in the previous year, the firm earned $3.31 EPS. The company’s quarterly revenue was down 6.7% compared to the same quarter last year. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.